Univ-Prof. Dr. Frederik Giesel, MD, MBA

Heinrich Heine University Düsseldorf

Curriculum Vitae

Professor Dr. Giesel is Chairman of the Nuclear Medicine Department at the University Hospital Düsseldorf/ GER. Alongside this, he is visiting Professor at the Osaka University/ Japan. Also, he had visiting professorships in renowned Universities such as Stanford University, USA and Yonsei University, South Korea.

Professor Giesel finished his studies in Medicine at the University of Mainz and Heidelberg /GER, before he went to the National Institutes of Health (NIH, Bethesda, USA) for some of his clerkship period. The specialization (residencies) began at the University Hospital Heidelberg and the German Cancer Research Center (DKFZ) with several scientific visits in the USA (NIH and Stanford University). During his residency, he also completed a two year executive MBA-program at the Frankfurt School of Finance/ GER with several courses abroad (London, Dubai, Tokyo, Boston). With the completion of his medical residencies (board certification) and habilitation, he took a further specialization in the field of nuclear medicine at the University Hospital Heidelberg/ GER. Through his still close connection with the basic medical sciences (pre-clinical school) Professor Giesel established the first combine series of seminars "Virtual Anatomy and Patho-Physiology" at the University of Heidelberg.

Professor Giesel has published over 300 scientific works (H-Index: 69). Furthermore, he acquired over the last years over 2.5 Mio Euro research funds in the field of imaging sciences and image post processing. Currently, his main research focuses are on the Phase I/II Multi-Center Study under his leadership, considering a new highly effective PET-Tracer (Prostate Specific Membrane Antigen [PSMA]), which has recently been introduced into the clinical environment for the diagnosis of prostate cancer and he also developed a novel so-called pan tumor tracer FAPI, in close cooperation with the Research Group of Prof. Haberkorn/UKHD.

Clinical emphases

- PSMA-PET/CT for the diagnosis of prostate cancer
- Oncological imaging
- Translational research process

Scientific focuses

- Translational molecular cancer imaging
- PSMA-PET
- PET with FAP-ligand (Fibroblast Activation Protein Inhibitor)
- Development of new oncological targets

Selected publications

Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers.
Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL. J Nucl Med. 2023 Nov;64(11):1712-1720. doi: 10.2967/jnumed.123.266046 *(IF 11.082)*

Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, Abe K, Miyake T, Shimazu K, Kobayashi S, Kurokawa Y, Eguchi H, Doki Y, Inohara H, Kato H, Mori Y, Cardinale J, Giesel FL. J Nucl Med. 2023 Aug;64(8):1225-1231. doi: 10.2967/jnumed.123.265486 *(IF 11.082)*

PSMA-GCK01 - A Generator-Based 99mTc-/188Re-Theranostic Ligand for the Prostate-Specific Membrane Antigen.
Cardinale J, Giesel FL, Wensky C, Rathke HG, Haberkorn U, Kratochwil C. J Nucl Med. 2023 Feb 9:jnumed.122.264944. doi: 10.2967/jnumed.122.264944 (IF 11.082)

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease.
Mori Y, Dendl K, Cardinale J, Kratochwil C, Giesel FL, Haberkorn U. Radiology. 2023 Jan 3:220749. doi: 10.1148/radiol.220749. PMID: 36594838 *(IF 29.146)*

Head-to-head intra-individual comparison of biodistribution and tumor uptake of (68)Ga-FAPI and (18)F-FDG PET/CT in cancer patients.
Giesel FL, Kratochwil C, Schlittenhardt J, Dendl K, Eiber M, Staudinger F, Kessler L, Fendler WP, Lindner T, Koerber SA, Cardinale J, et al. Eur J Nucl Med Mol Imaging. 2021 Jun 17. doi: 10.1007/s00259-021-05307-1. PMID: 34137945 *(IF 7.081)*

High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients.
Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, Sasaki H, Kamiya T, Shimosegawa E, Kato H, Cardinale J, Tateishi U, Nonomura N, Giesel FL. Ann Nucl Med. 2021 Apr;35(4):523-528. doi: 10.1007/s12149-021-01602-x. PMID: 33661475 *(IF 2.668)*

Diagnostic Accuracy of 18F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence.
Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, Eiber M, Weber WA, Rauscher I, Rahbar K, Schaefers M, Watabe T, Uemura M, Naka S, Nonomura N, Hatazawa J, Schwab C, Schütz V, Hohenfellner M, Holland-Letz T, Debus J, Kratochwil C, Amaral H, Choyke PL, Haberkorn U, Sandoval C, Giesel FL. J Nucl Med. 2021 Feb;62(2):208-213. doi: 10.2967/jnumed.120.246363. PMID: 32817141 *(IF 10.057)*

(68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.
Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967 *(IF 7.887)*

(225)Ac-PSMA-617 for Therapy of Prostate Cancer.
Kratochwil C, Haberkorn U, Giesel FL. Semin Nucl Med. 2020 Mar;50(2):133-140. doi: 10.1053/j.semnuclmed.2020.02.004. PMID: 32172798 *(IF 3.544)*

Radionuclide Therapy of Metastatic Prostate Cancer.
Kratochwil C, Haberkorn U, Giesel FL. Semin Nucl Med. 2019 Jul;49(4):313-325. doi: 10.1053/j.semnuclmed.2019.02.003 *(IF 3.544)*

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C. Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4 *(IF 7.704)*